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Background: A number of naturalistic studies have investigated paliperidone palmitate (PP) 
using proxy measures of effectiveness. An unexplored option is to examine the utility of the 
mental health clustering tool (MHCT), which is used in UK clinical practice to measure patient 
well-being and is linked to allocation of resources. This study evaluated the effectiveness of 
PP using the MHCT, the Health of the Nation Outcome Scales (HoNOS), and, for comparison, 
more conventional outcome measures.
Methods: This was a naturalistic, 1-year evaluation of PP (n=50) in schizophrenia as well as 
a comparator antipsychotic drugs group. Changes in the MHCT cluster-score cost ranking and 
four HoNOS-derived factors were analyzed using a mixed-model statistical analysis to explore 
the utility of these measures.
Results: At 1 year, 30 patients (60%) continued PP treatment. The mean “cluster-score cost 
ranking” (-1.5) and Severe Disturbance factor scores (-1.1) were significantly lower (p-value 
[adjusted] =0.0003, p-value [adjusted] =0.002, respectively) after 1 year of antipsychotic treat-
ment but no differences were found between PP and the comparator antipsychotic drugs group. 
Patients prescribed PP were 1.8 times (95% CI 1.1−3.1) more likely to be discharged from 
hospital than those in the comparator antipsychotic drugs group.
Conclusion: PP’s continuation rate after 1 year made the study similar to the existing evalua-
tions, and it was possible to prospectively evaluate antipsychotic effectiveness using the novel 
measures although these did not discriminate between PP and the comparator group. The 
investigation illustrates that in principle these novel measures are meaningful in naturalistic 
study designs.
Keywords: paliperidone palmitate, antipsychotics, schizophrenia, patient satisfaction, outcome 
measures
Plain language summary
We tried a new way of finding out if people with schizophrenia get better with medicines. 
We asked doctors to tell us when people were prescribed a medicine called paliperidone palmitate 
(PP). This medicine is for people with schizophrenia. When doctors answered special questions 
about how well people were doing on this medicine, we got a copy of the answers too. After a 
year, we compared answers for the medicine PP with answers for other medicines. We found 
that all medicines were making people feel better after a year. Our new way of finding out if 
people with schizophrenia get better is good. We also found that people with schizophrenia 
given PP in hospital were sent home sooner than people given other medicines.
Introduction
Paliperidone palmitate (PP) is a long-acting antipsychotic injection that was licensed 
for the maintenance treatment of adult patients with schizophrenia in 2009 in the 
USA and 2011 in Europe. A number of naturalistic studies have investigated PP in 
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clinical practice primarily using proxy measures of effective-
ness. An early UK example is the year-long follow-up of 
PP which utilized discontinuation rates, hospital bed days, 
and admission rates pre- and post-initiation of PP.1,2 Other 
papers (including clinical trials) have also reported on PP 
by measuring discontinuation3–5 and/or hospitalization (eg, 
readmission rates and number of bed days),3,6–11 as well as 
time to treatment failure12–14 as markers of clinical effec-
tiveness. Another hitherto unexplored option for reporting 
on the clinical effectiveness of PP in the UK is the use of 
the mental health clustering tool (MHCT) that incorporates 
an assessment of patient well-being and is used in routine 
clinical practice.
The MHCT is a tool used to assess the needs of patients 
with mental illness. It provides a “global description of a 
group of people with similar characteristics as identified by 
a holistic assessment”,15 allowing patients to be “clustered” 
into groups with the use of a set of question items that can 
be scored from 0 to 4. There are 21 care clusters of which 
seven are for psychosis (Table S1). The MHCT is in fact 
linked to the allocation of resources through Payment by 
Results (PbR), and in future the National Tariff prices, 
within the Quality and Outcome Framework (QoF) system of 
commissioning and funding mental health care in the UK.16 
It follows therefore that measuring whether patients move 
from one care cluster to another (when associated with indica-
tive costs) could be an indication of cost-effectiveness, which 
is explored as a primary outcome measure of the effective-
ness of PP in a year-long naturalistic setting in this study. 
The “four factors” described below were also incorporated 
into the current study.
The MHCT incorporates the Health of the Nation 
Outcome Scales (HoNOS) (Table S2). Speak and Hay17 
demonstrated that four clinically meaningful factors could 
be derived from HoNOS that were sensitive to change over 
time and could be used within the PbR QoF for working age 
and older adult mental health services, namely, Personal 
Well-Being, Emotional Well-Being, Social Well-Being, and 
Severe Disturbance. The current study sought to include the 
score for each of these four factors as part of the evaluation 
of PP effectiveness. This is the first evaluation that uses the 
MHCT to assess the clinical effectiveness of the introduction 
of an antipsychotic in clinical practice.
Finally, patient-reported outcomes, including treatment 
satisfaction, are considered to be important in the assess-
ment of therapeutic interventions, and a link has been 
shown between treatment satisfaction and an improvement 
in symptoms and adherence rates in schizophrenia.18 Thus, 
in line with other studies measuring patient satisfaction with 
PP,11,19 the medication satisfaction questionnaire (MSQ) was 
employed as the secondary outcome measure in this study.
aim of the study
The aim was to evaluate the effectiveness of PP by measuring 
and comparing (and therefore examining the utility) the MHCT 
cluster scores using their indicative costs, the four-factor 
scores derived from the HoNOS, and MSQ scores at baseline 
and 12 months. We utilized a comparator antipsychotic drugs 
group and also included hospital bed days and continua-
tion rates as part of our study in line with other studies.
Methods
compliance with ethical standards
This study was approved by the University of Reading’s 
Research Ethics Committee through the School Exemptions 
process reference number 10/13, on August 16, 2013.
This was a naturalistic, prospective service evaluation of PP 
prescribed for people diagnosed with schizophrenia in Berk-
shire Healthcare NHS Foundation Trust (BHFT). The decision 
to prescribe PP was made by a consultant psychiatrist, in consul-
tation with a multidisciplinary team, without the involvement of 
the study team. The prescriber completed paperwork to indicate 
the patient’s concurrent medication, general practitioner (GP) 
contact details, inpatient/outpatient status, diagnosis, and cluster 
score, which was passed on to a pharmacist coinvestigator (Kate 
Masters). After initiation of PP, patients followed their usual 
care pathway. Along with the initial baseline (T0) cluster data, 
if a patient continued with the treatment with PP at 6 months 
(T6) and 12 months (T12) further cluster data were inputted into 
electronic patient records by the care coordinator or a nurse. No 
separate consent was required for the study which was judged 
to be a service evaluation and approved by the Trust Clinical 
Audit Department on February 4, 2015. All adverse effects 
were recorded and reported to the manufacturer.
Each eligible prescription of PP was recorded on a secure, 
anonymized spreadsheet, and a researcher (Tamara Tompsett) 
used the electronic patient medical records to reconcile 
demographics to include age, gender, ethnicity, diagnosis, 
and details of the previous 12 months of antipsychotic use 
against each entry at T0. The prescriptions were monitored 
via electronic patient records for up to 12 months after ini-
tiation of PP. Once a patient was stabilized and discharged 
from the hospital, responsibility for prescribing medicine 
was generally passed to their GP although responsibility for 
monitoring therapy and completion of evaluation documents 
remained within BHFT. If PP treatment was stopped before 
T12, the data collected up to that point were entered into 
the study spreadsheet for statistical analysis. The reason for 
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discontinuation and, if applicable, any new antipsychotic 
medication prescribed were also recorded. Readmission rates 
and length of inpatient stay(s) from T0 to T12 and for the 
previous 12 months were also recorded in order to calculate 
the mean number of bed days pre- and post-PP prescribing 
and to calculate time to discharge (TTD) at treatment initia-
tion. For this element, the “index admission” was included 
in the analyses such that the “mirror” as described by Taylor 
et al9 was placed at the point of PP initiation.
By June 2015, a total of 78 patients were initiated to PP 
of which 50 were diagnosed with schizophrenia at the point 
of initiation. A primary outcome measure was the change in 
the MHCT cluster-score cost ranking at T12 compared to T0. 
To derive the cost ranking, clusters 10–17, relevant to patients 
with psychosis, were ranked from low to high cost using the 
expected reference cost (their predicted daily cost of care)20 
(Table S3). Thus, for example, cluster 11 “ongoing recur-
rent psychosis (low symptoms)” which was the “cheapest” 
cluster (cost per day £15.22) was ranked first, while cluster 
14 “a psychotic crisis”, the most “expensive” cluster (cost 
per day £86.23), was ranked eighth.
Another primary outcome measure was change in the 
four HoNOS-derived factors at T12 compared to T0. The 
score for each of the items of HoNOS was first retrieved 
from the original MHCT completed by the health professional 
assigning the care cluster. Then the individual scores for the 
items grouped by Speak and Hay17 to form that factor were 
aggregated on the study spreadsheet to derive the factor score. 
Thus, for example, for Personal Well-being, the factor score 
for each case was calculated by summing the scores assigned 
to each of items 4, 5, 10, and 12 and for Severe disturbance, 
the factor score for each case was calculated by summing 
scores assigned to each of items 1, and 6.
The secondary outcome measure was a change in patient 
medication satisfaction from T0 to T12 measured using the 
MSQ.21 The prescriber (and later, the care coordinator or a 
nurse) read out aloud the following question to the patient: 
“Overall, how satisfied are you with your current antipsy-
chotic medication(s)? 1= extremely dissatisfied, 2= very 
dissatisfied, 3= somewhat dissatisfied, 4= neither satisfied 
nor dissatisfied, 5= somewhat satisfied, 6= very satisfied, or 
7= extremely satisfied”, before circling the patient’s response 
on a sheet which was later returned to the researcher (Tamara 
Tompsett) for entry onto the study spreadsheet.
Trust approval was given to collate anonymized data on 
a comparator antipsychotic drugs group using information 
retrieved from the electronic patient database for any inpa-
tient from two acute wards at BHFT between January 2014 
and April 2014 with a diagnosis of schizophrenia using the 
F200 as a search term (from the International Statistical 
Classification of Diseases and Related Health Problems, 
ICD 1022). This was a convenience sample chosen to match 
the first 4 months of PP prescribing at the Trust. Patients were 
excluded from the comparator group if they were treatment 
resistant, had changed diagnosis, or were assigned to PP dur-
ing their admission. Patients were included in the comparator 
group if there were sufficient HoNOS data available within 
the electronic patient database over a continuous period of 
antipsychotic medication for 6 or 12 months (within 15% 
either side of these time points).
A mixed model was used to analyze the primary and 
secondary outcomes with “patient” treated as a random effect. 
Mixed models generalize the linear model methods to account 
for the presence of a hierarchical structure in the study and 
allow retention in the analysis of subjects with missing out-
comes. A total of 49 patients (one patient died and was excluded 
from the analysis) with schizophrenia receiving PP were com-
pared against 30 patients in the comparator group (with three 
being included twice to give 33 outcome measure points) for the 
primary outcomes. Reinclusion in the PP group was allowed. 
The MSQs were examined for the PP group only. The follow-
ing fixed effects were assessed: gender, age, age by gender 
interaction, time point (0, 6, and 12 months), and drug, and time 
point by drug. The repeated measurements nature of the records 
was modeled using an unstructured covariance pattern.
A mixed model for numerical outcomes was used for all 
four-factor outcomes. The effect measure used in this model 
was the absolute difference in mean of aggregate scores 
between evaluation at T0 and evaluation at T12.
A significance level of 5% was used and 95% CI for the 
true effect measure quantified. As multiple outcomes were 
analyzed, an adjustment for multiplicity was applied. Adjust-
ments for multiplicity were made using the Holm method for 
p-values and the Bonferroni method for confidence intervals. 
The package SAS 9.3 was used to fit the mixed models 
defined above. A Cox proportional hazards regression was 
used to model the TTD days for comparing PP to those in 
the comparator group. Descriptive statistics were used to 
summarize patient and medication characteristics. Means 
and standard deviations were calculated for continuous data 
and percentages for categorical data.
Results
Table 1 compares the demographic profile of 50 people with 
schizophrenia who continued/discontinued on PP at T6 and 
T12. Of these, 20 (40%) had discontinued (or were lost to follow 
up) by T12. This was because 8 (40% of this group) declined to 
receive a long-acting injection (LAI) with a preference for oral 
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medication, 3 (15%) had raised prolactin, 5 (25%) were due 
to perceived ineffectiveness (2 of which had ongoing tardive 
dyskinesia), 1 (5%) experienced drowsiness, 1 (5%) stopped 
all medications, 1 (5%) was lost to follow up, and 1 (5%) died 
due to a non-PP related cause. It is important to explain that the 
cause of death for the patient who died was judged by a coro-
ner to have been due to natural causes not associated with PP 
use. One patient (5%) was lost to contact after initiation of PP.
characteristics of patients treated 
with PP
Patients were aged between 22 and 65 years (mean 42 years). 
The majority of patients (n=33) were switched from risperi-
done (oral or LAI) before starting PP (Table 2). Those who 
stopped PP at T6 (n=14) were switched to clozapine (n=3), 
aripiprazole (n=3), oral risperidone (n=2), or other antipsy-
chotics (n=4). At T12, further 3 patients were switched to 
clozapine (total n=6), another to oral risperidone (total n=3), 
and one patient was discharged to their GP and declined to 
receive any further medication.
comparator group patients’ characteristics
Patients of the comparator group were aged between 22 and 
68 years (mean 42 years). The data related to 20 male patients 
(67%), 3 with data that were used twice as they switched antip-
sychotics, and 10 female patients (33%). The antipsychotics 
prescribed in the comparator group included aripiprazole (n=6), 
flupentixol decanoate (n=3), haloperidol (n=1), olanzapine 
(n=7), zuclopenthixol (n=6), trifluoperazine (n=1), pipotiazine 
palmitate (n=3), risperidone (n=4), and quetiapine (n=2).
analysis of MhcT cluster-score 
cost ranking
The mean cluster-score cost ranking at T0 was 4.2 (standard 
error [SE] 0.4) and lower at T6 with a mean of 2.9 (SE 0.5) 
and at T12 with a mean of 2.5 (SE 0.5) for PP. A similar 
Table 1 Demographic profile of 50 people with schizophrenia prescribed PP
Population Total 
(N=50a)
Continuation 
at 6 months 
(n=35)
Discontinuation 
before 6 months 
(n=14)
Continuation 
at 12 months 
(n=30)
Discontinuation 
before 12 months 
(n=20)
age (years)
Mean (± sD) 42 (13) 41 (13) 42 (13) 42 (14) 41 (14)
gender, n (%)
Male 38 (76) 27 (71) 11 (29) 24 (63) 14 (32)
Female 12 (24) 8 (67) 3 (25)a 6 (50) 5 (42)a
ethnicity, n (%)
Black 2 (4) 0 (0) 2 (100) 0 (0) 2 (100)
White 28 (56) 20 (71) 7 (25)a 17 (61) 10 (36)a
Otherb 19 (38) 15 (79) 4 (21) 13 (68) 6 (32)
Unknown 1 (2) 0 (0) 1 (100) 0 (0) 1 (100)
care setting, n (%)
inpatient 47 (94) 32 (68) 14 (30)a 27 (57) 19 (40)a
Outpatient 3 (6) 3 (100) 0 (0) 3 (100) 0 (0)
Treatment 12 months prior to PP, n (%)
risperidone oral/lai 24 (48) 17 (71) 6 (25)a 15 (63) 8 (33)a
risperidone oral/lai and other drug 9 (18) 7 (78) 2 (22) 6 (67) 3 (33)
None 2 (4) 1 (50) 1 (50) 1 (50) 1 (50)
Others 15 (30) 10 (67) 5 (33) 8 (53) 7 (47)
Comorbid substance use, n (%)
Yes 17 (34) 12 (71) 5 (29) 11 (65) 6 (35)
No 33 (66) 23 (70) 9 (27)a 19 (58) 13 (39)a
Notes: aOne lost to follow up (65 years, female, white) and one patient died, therefore percentages do not total 100% due to missing data. bOther ethnicity included 13 
asian or asian British.
Abbreviations: lai, long-acting injection; PP, paliperidone palmitate.
Table 2 MsQ descriptive statistics relating to paliperidone 
palmitate
Descriptive statistics T0 (n=50) T6 (n=35) T12 (n=30)
completed MsQ, n (%) 38 (76) 13 (37) 22 (74)
Not completed MsQ
lack of insight, n (%) 5 (10) n/a 4 (13)
refused, n (%) 1 (2) n/a n/a
Missing data, n (%) 6 (12) 22 (63) 4 (13)
least squares mean  
MsQ score (se)
3.8 (0.4) 5.3 (0.5)b 5.1 (0.4)c
rangea 1–7 2–7 3–7
Minimum value 1, n (%) 8 (21) 2 (15) 3 (14)
Maximum value 7, n (%) 3 (8) 3 (23) 1 (5)
Notes: T0, initial baseline; T6, treatment with PP at 6 months, and T12, 
treatment with PP at 12 months. aRange 1 (extremely dissatisfied) to 7 (extremely 
satisfied). bT6, p-value (adjusted) =0.0045, difference =1.5 (SE 0.47). cT12, p-value 
(adjusted) =0.0043, difference =1.34 (se 0.4).
Abbreviations: MSQ, Medication Satisfaction Questionnaire; n/a, not applicable; 
PP, paliperidone palmitate; se, standard error.
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trend was observed in the comparator antipsychotic drugs 
group. This downward trend in the mean cluster-score cost 
ranking was statistically significant for T0 versus T6 (p-value 
[adjusted (adj)] =0.01, difference =-1 [SE 0.4]) and T0 versus 
T12 (p-value [adj] =0.0003, difference =-1.5 [SE 0.4]). There 
were no statistically significant differences between PP and the 
other antipsychotic drugs group in terms of the pattern observed 
for reduction in the cluster-score cost ranking (Figure 1).
analysis of the four hoNOs-derived 
factors
The mean Severe Disturbance factor score at T0 was 3 (SE 0.4) 
for PP and lower at T6 with a mean of 2.2 (SE 0.4) and again at 
T12 with a mean of 2.2 (SE 0.4). A similar trend was observed 
in the comparator antipsychotic drugs group. This downward 
trend in the Severe Disturbance factor score was statisti-
cally significant for T0 versus T6 (p-value [adj] =0.0032, 
difference =-0.85 [SE 0.26]) and T0 versus T12 (p-value 
[adj] =0.002, difference =-1.1 [SE 0.3]). There were no 
statistically significant differences between PP and the other 
antipsychotic drugs group in terms of the pattern of reduction 
in the Severe Disturbance factor score (Figure 2).
There were no statistically significant reductions in 
the aggregated mean scores for the Personal Well-being, 
Emotional Well-being, or Social Well-being factors from 
T0 to T6 and T12 and no statistically significant differences 
in the pattern of these scores for PP compared to the other 
antipsychotic drugs group.
analysis of the MsQ scores
The mean MSQ score for PP was significantly higher at T6 
and T12, indicating a statistically significant improvement 
in patient medication satisfaction on use of PP. The mean 
MSQ score at T0 was 3.8 (SE 0.4), which increased to 5.3 
(SE 0.5) at T6 and to 5.1 (SE 0.4) at T12. The differences in 
mean MSQ scores were statistically significant for T0 versus 
T6 (p-value [adj] =0.0045, difference =1.5 [SE 0.47]) and 
T0 versus T12 (p-value [adj] =0.0043, difference =1.34 [SE 
0.4]) (Table 2).
Medication satisfaction increased in all 76% of the 
patients who completed an MSQ.
Mean number of bed days
There was a slight reduction in the mean number of bed days 
for the 30 patients who received PP up to T12 compared 
with the previous 12 months when they were on a differ-
ent drug. The mean number of bed days was 63.4 for the 
12 months before PP initiation compared with 61.6 days 
for the 12 months post PP initiation. This equates to a total 
reduction of 2.8% in the number of inpatient bed days for 
the 12 months after initiation of PP.
TTD
Of the 50 patients prescribed PP, data for 34 patients were 
available to calculate the TTD compared to 27 available 
data sets of hospital admissions in the comparator group 
(Figure 3). This was because n=9 discontinued prior to their 
Figure 1 Line graph to compare the least squares mean for the cluster score data of paliperidone palmitate and the other antipsychotic drugs group ranked by monetary 
costs per day (1 lowest cost to 7 highest cost).
Notes: Paliperidone palmitate (T0, n=48; T6, n=34; and T12, n=30) and other antipsychotic drugs group (T0 n=32, T6 n=21, and T12 n=28). T0, initial baseline; T6, 
treatment at 6 months; and T12, treatment at 12 months. aT0 versus T6, p-value (adj) =0.01, difference =-1 (se 0.4). bT0 versus T12, p-value (adj) =0.0003, difference =-1.5 
(se 0.4).
Abbreviations: adj, adjusted; se, standard error.
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discharge, n=4 were outpatients at time of prescribing, n=2 
had no records, and n=1 was in residential care.
The hazard for PP compared to the other antipsychotic 
drugs group is estimated to be 1.8 with 95% CI of 1.1−3.1. 
In other words, at any time point within the range of observed 
days to discharge (0.5–447) a patient on PP was 1.8 times 
more likely to be discharged than a patient on other antipsy-
chotics. The median number of days to discharge for patients 
on PP was 41 days compared to 63 days for the comparator 
antipsychotic drugs group.
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Figure 2 Clustered column chart to compare the least squares mean for the aggregated scores (0–8) of Severe Disturbance for paliperidone palmitate and the other 
antipsychotic drugs group.
Notes: Severe Disturbance, containing overactive, aggressive, disruptive, or agitated behavior and problems associated with hallucinations and delusions (scales 1 and 6 
from hoNOs). Paliperidone palmitate (T0, n=48; T6, n=34; and T12, n=30) and other antipsychotic drugs group (T0, n=32; T6, n=21; and T12, n=28). T0, initial baseline; 
T6, treatment at 6 months; and T12, treatment at 12 months. aT0 versus T6, p-value (adj) =0.0032, difference =0.85 (SE 0.26). bT0 versus T12, p-value (adj) =0.002, 
difference =1.1 (se 0.3).
Abbreviations: adj, adjusted; hoNOs, health of the Nation Outcome scales; se, standard error.
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Figure 3 Cox PH regression showing the time to discharge of patients prescribed either PP (n=34) or those in the other antipsychotic drugs group (n=27).
Abbreviations: Ph, proportional hazards; PP, paliperidone palmitate; PPlai, paliperidone palmitate long-acting injection.
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Discussion
In this year-long follow-up, 60% of 50 patients continued 
treatment with PP, which made the study similar to the exist-
ing evaluations on this measure. Using a mixed-model sta-
tistical analysis we found that the mean MHCT cluster-score 
cost ranking and the HoNOS-derived Severe Disturbance 
factor score were each significantly lower after 1 year of 
treatment with either PP or the comparator antipsychotic 
drugs group. There were no statistically significant reduc-
tions in the other HoNOS-derived factors. Patient satisfaction 
was significantly higher after 1 year of treatment with PP 
compared to baseline. We found a modest reduction in the 
mean number of bed days for patients who continued with 
PP in the year following treatment compared to the previous 
12 months. In addition, we found that a patient on PP was 
1.8 times more likely to be discharged from hospital than a 
patient in the comparator group of antipsychotics.
Other studies have reported similar continuation rates 
(65% and 60%) after 1 year of treatment with PP.1,4 In this 
respect, our study is comparable to existing literature although 
it is important to acknowledge that a 40% discontinuation 
rate is a limitation of this paper. The main reason for PP dis-
continuation in our study was patient refusal of medication 
followed by raised prolactin levels and perceived medication 
ineffectiveness. Other studies have found the reason for PP 
discontinuation at 1 year to be perceived ineffectiveness more 
frequently than the experience of side effects and refusal of 
treatment.1–3 In our study, perceived ineffectiveness was the 
reason for PP discontinuation in 25% of the cases, whereas 
patient refusal of treatment accounted for 40%. This differ-
ence could be due to chance and the relatively small size of 
our sample compared to other studies.
For those who did continue with PP for 12 months, 74% 
completed the MSQ, showing a statistically significant 
improvement in their medication satisfaction scores with 
treatment. A review of the literature regarding patients’ 
satisfaction with antipsychotic medication for schizophre-
nia highlighted that as well as the more obvious negative 
effects upon satisfaction of drug side-effects, the lack of 
involvement in treatment planning or decision making was 
a major influence on satisfaction ratings.23 The improvement 
we found in the mean MSQ scores at 12 months (compared 
to baseline scores) was 1.5 points, which is slightly higher 
than that reported in other studies: 0.88 points at 21 weeks19 
and 0.8 points at 12 months.11 The improvement though, 
as well as the significant reduction found in the HoNOS-
derived Severe Disturbance factor, described below, over 
the 12-month treatment period suggests that medication 
satisfaction with PP treatment is aligned to a reduction in 
the severity of psychotic symptoms.
PP resulted in a significant reduction in the indicative 
costs associated with MHCT cluster-score cost ranking as 
well as the HoNOS-derived Severe Disturbance factor score 
at 12 months, indicating benefit from treatment. This reduc-
tion was similar to a comparator group. On the one hand, 
these findings suggest that the MHCT- and HoNOS-related 
measures are useable for evaluating antipsychotic effective-
ness over a 1-year treatment period. After all, those who 
continue treatment over a 1-year period would be expected to 
receive tangible benefit from their medication, and finding a 
reduction in these scores (and specifically Severe Disturbance 
by virtue of measuring illness severity) is in line with that 
expectation. One might infer that PP was at least as good as a 
multitude of other antipsychotics prescribed for the treatment 
of schizophrenia according to these novel outcome measures. 
On the other hand, it could be argued that cluster-score cost 
rankings and HoNOS-derived factor scores, although use-
able, are not sufficiently sensitive to discriminate between 
PP and the other antipsychotics, if such a difference exists. 
It is a fairly common limitation of naturalistic studies to 
not include a comparator group. Although our comparator 
group was small (n=33), it provides a useful indicator that 
the novel measures of this study are usable with PP as well 
as other antipsychotics.
One limitation of this evaluation is that the accuracy 
and reliability of the MHCT cluster and HoNOS scoring 
were accepted at face value. Across the mental health sector 
there has been an investment to report data based upon the 
MHCT in an effort to standardize practices and improve the 
reliability of this tool as a possible foundation for patients’ 
mental health funding. However, for the MHCT to be useful, 
the accuracy with which it is applied needs to be monitored. 
An error rate of 40% has been observed in an audit of 540 
initial or changes to patient clusters made by health profes-
sional completing the clustering.24 Nonetheless, it is thought 
that clusters will remain the mandated currency for mental 
health care with the payment period being based upon an 
episode of care, not contacts or bed days.25 The 5-year for-
ward view for mental health in the UK wishes to remove 
unaccountable block contracts for mental health payments, 
with providers not rewarded for providing days of care but 
initiating whole pathways of care.26 This evaluation is impor-
tant as it found that compared to baseline and after 12 months 
of consistent antipsychotic treatment, MHCT cluster-score 
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cost ranking and HoNOS-derived Severe Disturbance factor 
scores can be sensitive to change, in contrast to little change in 
the number of inpatient bed days over 1 year of treatment with 
PP when compared to the 1-year period prior to treatment.
The PP continuation rate after 1 year made the study 
similar to the existing evaluations, while it was also pos-
sible to prospectively evaluate antipsychotic effectiveness 
using the MHCT and the HoNOS as well as the MSQ. 
Patients who continued with PP treatment over 12 months 
were significantly more satisfied when compared to baseline 
satisfaction data relating to their previous medications. Treat-
ment of patients with schizophrenia was shown to result in a 
significant reduction in the MHCT cluster-score cost ranking 
and a significant reduction in the HoNOS-derived Severe 
Disturbance factor scores over 12 months of antipsychotic 
treatment. The investigation illustrates that in principle these 
novel measures are meaningful in naturalistic study designs.
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Supplementary materials
Table S1 Key to MhcT care clusters 10–17 (“psychosis” super cluster)
Care cluster Description and likely primary diagnosis
Care cluster 10: first 
episode psychosis
This group will be presenting to the service for the first time with mild to severe psychotic phenomena. They may 
also have depressed mood and/or anxiety or other behaviors. Drinking or drug-taking may be present but will 
not be the only problem. Likely to include (F20–F29) schizophrenia, schizotypal and delusional disorders, and F31 
bipolar disorder.
care cluster 11: ongoing 
recurrent psychosis (low 
symptoms)
This group has a history of psychotic symptoms that are currently controlled and causing minor problems if any at 
all. They are currently experiencing a sustained period of recovery where they are capable of full or near functioning. 
However, there may be impairment in self-esteem and efficacy and vulnerability to life. Likely to include (F20–F29) 
schizophrenia, schizotypal and delusional disorders, F30 manic episode, and F31 bipolar affective disorder.
care cluster 12: ongoing 
or recurrent psychosis 
(high disability)
This group has a history of psychotic symptoms with a significant disability with major impact on role functioning. 
They are likely to be vulnerable to abuse or exploitation. Likely to include (F20–F29) schizophrenia, schizotypal and 
delusional disorders, F30 manic episode, F31 bipolar affective disorder.
care cluster 13: ongoing 
or recurrent psychosis 
(high symptom and 
disability)
This group will have a history of psychotic symptoms which are not controlled. They will present with severe to 
very severe psychotic symptoms and some anxiety or depression. They have a significant disability with major impact 
on role functioning. likely to include (F20–F29) schizophrenia, schizotypal and delusional disorders, F30 manic 
episode, and F31 bipolar affective disorder.
care cluster 14: psychotic 
crisis
They will be experiencing an acute psychotic episode with severe symptoms that cause severe disruption to 
role functioning. They may present as vulnerable and a risk to others or themselves. Likely to include (F20–F29) 
schizophrenia, schizotypal and delusional disorders, F30 manic episode, and F31 bipolar affective disorder.
Care cluster 15: severe 
psychotic depression
This group will be suffering from an acute episode of moderate to severe depressive symptoms. Hallucinations 
and delusions will be present. It is likely that this group will present a risk of non-accidental self-injury and have 
disruption in many areas of their lives. likely to include, F32.3 severe depressive episode with psychotic symptoms.
care cluster 16: psychosis 
and affective disorder 
(high substance misuse 
and engagement)
This group has enduring, moderate to severe psychotic or bipolar affective symptoms with unstable, chaotic lifestyles 
and co-existing problem drinking or drug taking. They may present a risk to self and others and engage poorly with 
services. Role functioning is often globally impaired. Likely to include (F10–F19) mental and behavioral disorders due 
to psychoactive substance use, (F20–F29) schizophrenia, schizotypal and delusional disorders, and bipolar disorder.
care cluster 17: psychosis 
and affective disorder – 
difficult to engage
This group has moderate to severe psychotic symptoms with unstable, chaotic lifestyles. There may be some 
problems with drugs or alcohol not severe enough to warrant care associated with cluster 16. This group 
has a history of non-concordance, is vulnerable and engages poorly with services. Likely to include (F20–F29) 
schizophrenia, schizotypal and delusional disorders, and bipolar.
Notes: adapted with permission from Mental Health Clustering Booklet (V5.0) (2016/17). Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/499475/Annex_B4_Mental_health_clustering_booklet.pdf.1 The ‘F’ codes are defined by the International Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD-10)-WHO Version for 2016.2
Abbreviation: MhcT, mental health clustering tool.
Table S2 Key to individual hoNOs items
HoNOS scales Title of scales
item 1 Overactive, aggressive, disruptive or agitated behavior
item 2 Non-accidental self-injury
item 3 Problem drinking or drug taking
item 4 Cognitive problems
Item 5 Physical illness or disability problems
item 6 hallucinations and delusions
item 7 Depressed mood
item 8 Other mental and behavioral problems
item 9 Problems with relationships
item 10 Problems with activities of daily living
item 11 Problems with living conditions
item 12 Problems with occupation and activities
item 13 Strong unreasonable beliefs
Note: Adapted from Health of the Nation Outcome Scales (HoNOS). Available from: https://www.rcpsych.ac.uk/pdf/HoNOS-secure%20Glossary%20v2b%20Feb%2007.pdf. 
©royal college of Psychiatrists 1996.3
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Table S3 Cluster-score cost ranking according to financial outlay
Cluster score Indicative cluster costs value/day (£) Linear ranking
10 29.06 3
11 15.22 1
12 26.45 2
13 40.57 5
14 86.23 8
15 46.56 6
16 35.84 4
17 53.24 7
Notes: The indicative cluster costs are derived from 2011 to 2012 reference costs. Nhs. Payment by Results Guidance for 2013–14; 2013. Available from: https://www.gov.
uk/government/uploads/system/uploads/attachment_data/file/232162/Mental_Health_PbR_Guidance_for_2013-14.pdf.4
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